Wall Street analysts forecast that Uniqure NV (NASDAQ:QURE) will report earnings of ($0.83) per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Uniqure’s earnings, with the highest EPS estimate coming in at ($0.79) and the lowest estimate coming in at ($0.87). Uniqure posted earnings per share of ($0.59) during the same quarter last year, which indicates a negative year over year growth rate of 40.7%. The business is expected to issue its next quarterly earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Uniqure will report full year earnings of ($3.22) per share for the current year, with EPS estimates ranging from ($3.40) to ($3.10). For the next financial year, analysts anticipate that the business will post earnings of ($3.43) per share, with EPS estimates ranging from ($4.15) to ($2.67). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Uniqure.
Uniqure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, July 29th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.08). Uniqure had a negative net margin of 1,232.30% and a negative return on equity of 61.67%. The company had revenue of $2.47 million for the quarter, compared to analyst estimates of $1.53 million.
Uniqure stock traded up $3.52 during mid-day trading on Monday, reaching $46.02. 1,205,302 shares of the company traded hands, compared to its average volume of 593,943. The company has a debt-to-equity ratio of 0.51, a current ratio of 8.07 and a quick ratio of 8.07. Uniqure has a fifty-two week low of $21.98 and a fifty-two week high of $82.49. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -19.67 and a beta of 0.84. The firm’s fifty day moving average is $44.23 and its two-hundred day moving average is $58.68.
In related news, Director Philip Astley-Sparke sold 6,460 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $60.12, for a total transaction of $388,375.20. Following the sale, the director now directly owns 12,406 shares of the company’s stock, valued at $745,848.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $56.48, for a total transaction of $451,840.00. Following the sale, the chief executive officer now directly owns 391,230 shares in the company, valued at $22,096,670.40. The disclosure for this sale can be found here. Insiders sold a total of 35,229 shares of company stock worth $1,802,041 over the last ninety days. Insiders own 2.91% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. State of New Jersey Common Pension Fund D acquired a new stake in Uniqure during the third quarter worth approximately $1,287,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Uniqure by 21.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,975 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 346 shares during the period. Assenagon Asset Management S.A. acquired a new position in Uniqure in the 3rd quarter valued at $3,076,000. Henry James International Management Inc. increased its stake in Uniqure by 7.1% in the 3rd quarter. Henry James International Management Inc. now owns 113,358 shares of the biotechnology company’s stock valued at $4,462,000 after buying an additional 7,514 shares during the period. Finally, Macquarie Group Ltd. increased its stake in Uniqure by 1.9% in the 2nd quarter. Macquarie Group Ltd. now owns 693,000 shares of the biotechnology company’s stock valued at $54,158,000 after buying an additional 13,000 shares during the period. 69.87% of the stock is currently owned by hedge funds and other institutional investors.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Read More: Trading on Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.